Wearable and implantable intraocular pressure (IOP) biosensors offer a promising, patient-centered approach to glaucoma management by enabling continuous, real-time monitoring of intraocular pressure, according to a presentation at the 2025 ASCRS Annual Meeting.
Researchers analyzed both preclinical and clinical data on devices designed to track IOP fluctuations in real time.
The analysis found that these innovative sensors offer improved accuracy, sensitivity, and patient convenience, allowing for continuous data collection that traditional snapshot measurements often miss. This is particularly crucial for detecting pressure spikes in patients with normal-tension glaucoma or diurnal IOP fluctuations.
Some biosensors have already received FDA approval, supporting their integration into teleophthalmology and personalized treatment plans. While challenges remain, particularly regarding long-term use and market adoption, the technology shows strong potential to reshape patient-centered glaucoma care. Researchers emphasize the need for further cost-effectiveness studies to support widespread clinical implementation.
Reference
Yang Wu K, et al. Innovative IOP Monitoring in Glaucoma: Wearable and Implantable Biosensors. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting; April 25–28, 2025; Los Angeles, CA.
Related Content
